Anavip

Anavip
Clinical data
Trade names	Anavip
Other names	Crotalidae immune F(ab')2 (equine); Viper antivenom;
AHFS/Drugs.com	Monograph
Legal status
Legal status	US: ℞-only;
Identifiers
PubChem SID	482023934;
DrugBank	DB14114;
UNII	92VV7G83ED;

Anavip is the brand name of a snake antivenin indicated for the management of people with North American rattlesnake envenomation.^[3]^[4]^[1] As defined by the US Food and Drug Administration (FDA), the proper name is crotalidae immune F(ab')2 (equine).^[2] It is manufactured by Rare Disease Therapeutics.

Anavip is a divalent fragment antigen-binding protein, F(ab')₂, derived from the blood of horses immunized with the venom of the snakes Bothrops asper and Crotalus durissus. The product is produced by pepsin digestion of horse blood plasma then purified resulting in a preparation containing >85% F(ab')₂.^[1]

References

1 2 3 "Anavip crotalidae immune F(ab')2 (equine) Lyophilized Powder for Solution for Injection For Intravenous Use Only" (PDF). Rare Disease Therapeutics. Retrieved 18 August 2020.
1 2 "Anavip". U.S. Food and Drug Administration (FDA). 1 April 2021. STN: 125488. Retrieved 3 October 2025.
↑ Cocchio C, Johnson J, Clifton S (January 2020). "Review of North American pit viper antivenoms". American Journal of Health-System Pharmacy. 77 (3): 175–187. doi:10.1093/ajhp/zxz278. PMID 31974558.
↑ "Marketing authorization with orphan designation - USA". orpha.net. orphanet. Retrieved 19 August 2020.